Search - tctmd.com

Displaying 481 - 500 of 600

Sort: Relevancy | Date

News Conference News TCT 2014

SYMPLICITY HTN-3 Substudy Examines BP Response Factors in African Americans

Yael L. Maxwell

September 15, 2014

News Industry News

REPRISE II Data Demonstrate Sustained Safety And Performance Outcomes At One Year For The Boston Scientific Lotus™ Valve System

September 15, 2014

News Industry News

Twelve-Month Data from St. Jude Medical EnligHTN Renal Denervation System Show Continued Safety and Efficacy for Patients

September 13, 2014

News Industry News

Two Year Data from FAME 2 Trial Shows Sustained Benefits of FFR-Guided PCI over Medical Treatment in Patients with Stable CAD

September 02, 2014

News Conference News ESC 2014

SYMPLICITY HTN-3: Renal Denervation Still Safe, Not Effective at 1 Year

Todd Neale

September 01, 2014

News Industry News

New Clinical Trial Results Demonstrate Importance of St. Jude Medical Fractional Flow Reserve in Guiding Treatment of NSTEMI Patients

September 01, 2014

News Conference News ESC 2014

SOLID-TIMI 52: Darapladib Fails to Reduce Adverse Events After ACS

Yael L. Maxwell

August 31, 2014

News Industry News

Miracor Medical Systems begins European launch of its next-generation PICSO® Impulse System

July 22, 2014

News Industry News

The Medicines Company Receives Market Authorization Renewal for Angiox® (Bivalirudin) from the European Medicines Agency and the European Commission

July 07, 2014

News Daily News

High-Dose Edoxaban as Effective as Warfarin for Stroke Prevention in A-fib

Yael L. Maxwell

June 27, 2014

News Features

Renal Denervation 2.0: Laying Out the Road to Recovery from Symplicity HTN-3

June 24, 2014

News Features

Renal Denervation 2.0: Assessing the Failure of a Pivotal Trial

June 18, 2014

News Daily News

SYMPLICITY HTN-2: Renal Denervation Safe, Effective at 3 Years

Yael L. Maxwell

June 11, 2014

News Industry News

St. Jude Medical and CardioMEMS Announce FDA Approval of the CardioMEMS Heart Failure Management System

May 28, 2014

News Industry News

FDA Approves First Implantable Wireless Device with Remote Monitoring to Measure Pulmonary Artery Pressure in Certain Heart Failure Patients

May 28, 2014

News Conference News EuroPCR 2014

SYMPLICITY HTN-3: Predictors of Response Still Relevant After Trial’s Negative Findings

Yael L. Maxwell

May 22, 2014

News Industry News

Preliminary Results From the St. Jude Medical EnligHTN III Study Demonstrate Renal Denervation Is Safe and Effective

May 22, 2014

News Conference News EuroPCR 2014

Global SYMPLICITY Substudy Teases out Reasons for Non-response in Real-World Patients

Yael L. Maxwell

May 22, 2014

News Industry News

Data on Angiox (Bivalirudin Injection) in Heart Attack Patients Presented at EuroPCR and Published in European Heart Journal

May 22, 2014

News Industry News

Mounting Scientific Evidence Supports Role of Power Plate® Whole Body Vibration in Lowering Blood Pressure

May 15, 2014

Advertisement

SYMPLICITY HTN-3 Substudy Examines BP Response Factors in African Americans

REPRISE II Data Demonstrate Sustained Safety And Performance Outcomes At One Year For The Boston Scientific Lotus™ Valve System

Twelve-Month Data from St. Jude Medical EnligHTN Renal Denervation System Show Continued Safety and Efficacy for Patients

Two Year Data from FAME 2 Trial Shows Sustained Benefits of FFR-Guided PCI over Medical Treatment in Patients with Stable CAD

SYMPLICITY HTN-3: Renal Denervation Still Safe, Not Effective at 1 Year

New Clinical Trial Results Demonstrate Importance of St. Jude Medical Fractional Flow Reserve in Guiding Treatment of NSTEMI Patients

SOLID-TIMI 52: Darapladib Fails to Reduce Adverse Events After ACS

Miracor Medical Systems begins European launch of its next-generation PICSO® Impulse System

The Medicines Company Receives Market Authorization Renewal for Angiox® (Bivalirudin) from the European Medicines Agency and the European Commission

High-Dose Edoxaban as Effective as Warfarin for Stroke Prevention in A-fib

Renal Denervation 2.0: Laying Out the Road to Recovery from Symplicity HTN-3

Renal Denervation 2.0: Assessing the Failure of a Pivotal Trial

SYMPLICITY HTN-2: Renal Denervation Safe, Effective at 3 Years

St. Jude Medical and CardioMEMS Announce FDA Approval of the CardioMEMS Heart Failure Management System

FDA Approves First Implantable Wireless Device with Remote Monitoring to Measure Pulmonary Artery Pressure in Certain Heart Failure Patients

SYMPLICITY HTN-3: Predictors of Response Still Relevant After Trial’s Negative Findings

Preliminary Results From the St. Jude Medical EnligHTN III Study Demonstrate Renal Denervation Is Safe and Effective

Global SYMPLICITY Substudy Teases out Reasons for Non-response in Real-World Patients

Data on Angiox (Bivalirudin Injection) in Heart Attack Patients Presented at EuroPCR and Published in European Heart Journal

Mounting Scientific Evidence Supports Role of Power Plate® Whole Body Vibration in Lowering Blood Pressure

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content